OpenLB
Open Library of Bioscience
Advanced Search
International journal of molecular sciences
May 25, 2021;22 (11):

The Potential of Aptamer-Mediated Liquid Biopsy for Early Detection of Cancer.

Dhruvajyoti Roy, Andreas Pascher, Mazen A Juratli, Judith C Sporn
Author Information
  1. Dhruvajyoti Roy: Helio Health, Irvine, CA 92618, USA. ORCID
  2. Andreas Pascher: Department of General, Visceral and Transplant Surgery, University Hospital Münster, 48149 Münster, Germany.
  3. Mazen A Juratli: Department of General, Visceral and Transplant Surgery, University Hospital Münster, 48149 Münster, Germany. ORCID
  4. Judith C Sporn: Department of General, Visceral and Transplant Surgery, University Hospital Münster, 48149 Münster, Germany.
PMID: 34070509 DOI: 10.3390/ijms22115601

Abstract

The early detection of cancer favors a greater chance of curative treatment and long-term survival. Exciting new technologies have been developed that can help to catch the disease early. Liquid biopsy is a promising non-invasive tool to detect cancer, even at an early stage, as well as to continuously monitor disease progression and treatment efficacy. Various methods have been implemented to isolate and purify bio-analytes in liquid biopsy specimens. Aptamers are short oligonucleotides consisting of either DNA or RNA that are capable of binding to target molecules with high specificity. Due to their unique properties, they are considered promising recognition ligands for the early detection of cancer by liquid biopsy. A variety of circulating targets have been isolated with high affinity and specificity by facile modification and affinity regulation of the aptamers. In this review, we discuss recent progress in aptamer-mediated liquid biopsy for cancer detection, its associated challenges, and its future potential for clinical applications.

Keywords

DNA-nanostructures aptamer circulating biomarkers circulating tumor cells early cancer detection extracellular vesicles liquid biopsy non-invasive diagnosis

References

  1. Adv Mater. 2013 Apr 24;25(16):2368-73 [PMID: 23495071]
  2. Adv Mater. 2014 Nov 19;26(43):7333-8 [PMID: 25251012]
  3. Clin Cancer Res. 2020 Apr 15;26(8):1886-1895 [PMID: 32015020]
  4. J Am Chem Soc. 2013 Nov 6;135(44):16438-45 [PMID: 24164620]
  5. ACS Appl Mater Interfaces. 2016 May 25;8(20):12638-43 [PMID: 27176724]
  6. Mol Ther Nucleic Acids. 2014 Aug 12;3:e184 [PMID: 25118170]
  7. Small. 2016 Feb 10;12(6):727-32 [PMID: 26707703]
  8. PLoS One. 2015 Sep 14;10(9):e0137613 [PMID: 26367280]
  9. Biomed Res Int. 2016;2016:5735869 [PMID: 27119081]
  10. Small. 2019 Nov;15(47):e1903600 [PMID: 31588683]
  11. Cancers (Basel). 2017 Jun 21;9(6): [PMID: 28635657]
  12. J Natl Cancer Inst. 2015 Nov 22;108(3): [PMID: 26598503]
  13. JAMA Oncol. 2015 Sep;1(6):778-84 [PMID: 26203912]
  14. ACS Appl Mater Interfaces. 2017 Oct 11;9(40):34706-34714 [PMID: 28925689]
  15. Methods. 2016 Mar 15;97:88-93 [PMID: 26500145]
  16. Science. 2000 Feb 4;287(5454):820-5 [PMID: 10657289]
  17. Biotechnol Bioeng. 2018 Mar;115(3):536-544 [PMID: 29105734]
  18. J Exp Clin Cancer Res. 2018 Oct 5;37(1):245 [PMID: 30290833]
  19. Biomaterials. 2014 Aug;35(25):6998-7007 [PMID: 24857291]
  20. Anal Chem. 2018 Dec 18;90(24):14402-14411 [PMID: 30350954]
  21. Biomed Rep. 2017 Jun;6(6):615-626 [PMID: 28584632]
  22. Anal Bioanal Chem. 2015 Nov;407(29):8883-92 [PMID: 26449846]
  23. Trends Pharmacol Sci. 2019 Mar;40(3):172-186 [PMID: 30736982]
  24. Theranostics. 2015 Jan 01;5(1):23-42 [PMID: 25553096]
  25. Mol Ther. 2012 Jun;20(6):1242-50 [PMID: 22434135]
  26. Anal Chem. 2007 Jul 1;79(13):4900-7 [PMID: 17530817]
  27. Anal Chem. 2018 Apr 3;90(7):4507-4513 [PMID: 29512380]
  28. Anal Chem. 2014 Jul 1;86(13):6572-9 [PMID: 24914856]
  29. J Immunol Res. 2016;2016:1083738 [PMID: 27413756]
  30. Biosens Bioelectron. 2019 Oct 1;142:111503 [PMID: 31376716]
  31. Biomedicines. 2020 Aug 26;8(9): [PMID: 32858879]
  32. J Clin Invest. 2014 Jul;124(7):2977-87 [PMID: 24892807]
  33. EMBO Mol Med. 2014 Nov 14;7(1):1-11 [PMID: 25398926]
  34. Cancer Immunol Res. 2014 Sep;2(9):867-77 [PMID: 24938283]
  35. Anal Chem. 2012 Mar 20;84(6):2647-53 [PMID: 22283623]
  36. Biotechnol Bioeng. 2015 Aug;112(8):1506-22 [PMID: 25727321]
  37. Nat Commun. 2021 May 5;12(1):2536 [PMID: 33953198]
  38. J Biol Chem. 2001 Dec 28;276(52):48644-54 [PMID: 11590140]
  39. PLoS One. 2011;6(9):e24910 [PMID: 21949784]
  40. Biochem Biophys Res Commun. 2017 Oct 21;492(3):507-512 [PMID: 28822765]
  41. Mol Ther Nucleic Acids. 2015 Apr 28;4:e237 [PMID: 25919090]
  42. J Nanobiotechnology. 2017 Nov 13;15(1):81 [PMID: 29132385]
  43. Anal Chem. 2018 Jun 5;90(11):6702-6709 [PMID: 29722265]
  44. Theranostics. 2015 Jun 06;5(9):985-94 [PMID: 26155314]
  45. Small. 2019 May;15(19):e1900735 [PMID: 30963720]
  46. Angew Chem Int Ed Engl. 2019 Feb 18;58(8):2236-2240 [PMID: 30548959]
  47. Anal Chem. 2015 Jan 20;87(2):1411-9 [PMID: 25495441]
  48. Adv Healthc Mater. 2018 Oct;7(20):e1800484 [PMID: 30009550]
  49. Biotechnol Adv. 2015 Nov 1;33(6 Pt 2):1141-61 [PMID: 25708387]
  50. Cancers (Basel). 2014 Jan 15;6(1):128-42 [PMID: 24434542]
  51. Science. 2018 Feb 23;359(6378):926-930 [PMID: 29348365]
  52. Molecules. 2019 Mar 07;24(5): [PMID: 30866536]
  53. Anal Chem. 2013 Apr 16;85(8):4141-9 [PMID: 23480100]
  54. Curr Med Chem. 2011;18(27):4195-205 [PMID: 21838686]
  55. Talanta. 2019 Jul 1;199:674-678 [PMID: 30952314]
  56. Mol Ther Nucleic Acids. 2014 Aug 05;3:e183 [PMID: 25093707]
  57. Proc Natl Acad Sci U S A. 2013 May 14;110(20):7998-8003 [PMID: 23630258]
  58. J Cell Physiol. 2019 Feb;234(2):1416-1425 [PMID: 30078189]
  59. Nucleic Acids Res. 2015 Jul 13;43(12):e82 [PMID: 26007661]
  60. Biosens Bioelectron. 2017 Jun 15;92:8-15 [PMID: 28167415]
  61. Angew Chem Int Ed Engl. 2018 Nov 26;57(48):15675-15680 [PMID: 30291794]
  62. Anal Chim Acta. 2006 Mar 30;564(1):91-6 [PMID: 17723366]
  63. Lab Chip. 2009 May 7;9(9):1206-12 [PMID: 19370238]
  64. Clin Chem. 2009 Apr;55(4):813-22 [PMID: 19246617]
  65. Biomaterials. 2015 Oct;67:274-85 [PMID: 26231918]
  66. Nanoscale. 2018 May 17;10(19):9053-9062 [PMID: 29718044]
  67. Small. 2018 Feb;14(6): [PMID: 29282861]
  68. Nat Biomed Eng. 2019 Mar;3(3):183-193 [PMID: 30948809]
  69. Nucleic Acid Ther. 2015 Jun;25(3):162-72 [PMID: 25894736]
  70. Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):2989-94 [PMID: 19202068]
  71. Anal Chem. 2015;87(9):4941-8 [PMID: 25867099]
  72. Angew Chem Int Ed Engl. 2009;48(35):6494-8 [PMID: 19623590]
  73. J Am Chem Soc. 2016 Mar 2;138(8):2476-9 [PMID: 26860321]
  74. Tumour Biol. 2017 Jul;39(7):1010428317717123 [PMID: 28718373]
  75. ACS Nano. 2013 Aug 27;7(8):7067-76 [PMID: 23837646]
  76. Science. 1990 Aug 3;249(4968):505-10 [PMID: 2200121]
  77. J Biol Chem. 2014 Mar 21;289(12):8706-19 [PMID: 24415766]
  78. Cancer Res. 2003 Nov 1;63(21):7483-9 [PMID: 14612549]
  79. Sci Rep. 2015 May 19;5:10266 [PMID: 25988257]
  80. Nat Biomed Eng. 2017;1: [PMID: 28966872]
  81. Anal Chim Acta. 2018 Oct 31;1029:58-64 [PMID: 29907291]
  82. Mol Ther. 2011 Oct;19(10):1878-86 [PMID: 21829171]
  83. Clin Ther. 2016 Jul;38(7):1551-66 [PMID: 27158009]
  84. Methods Mol Biol. 2014;1103:241-65 [PMID: 24318899]
  85. Cancer Res. 2012 Mar 15;72(6):1373-83 [PMID: 22282665]
  86. ACS Nano. 2010 Mar 23;4(3):1433-42 [PMID: 20166743]
  87. Angew Chem Int Ed Engl. 2019 Jun 24;58(26):8719-8723 [PMID: 31095853]
  88. Biosens Bioelectron. 1999 May 31;14(5):457-64 [PMID: 10451913]
  89. Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):5979-5984 [PMID: 30858327]
  90. Nucleic Acid Ther. 2013 Dec;23(6):443-9 [PMID: 24256293]
  91. Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15416-21 [PMID: 14676325]
  92. ACS Sens. 2019 May 24;4(5):1245-1251 [PMID: 30915846]
  93. Head Neck. 2014 Aug;36(8):1207-15 [PMID: 23913663]
  94. Crit Rev Oncol Hematol. 2021 Jan;157:103187 [PMID: 33276181]
  95. Nat Rev Drug Discov. 2010 Jul;9(7):537-50 [PMID: 20592747]
  96. Nature. 1990 Aug 30;346(6287):818-22 [PMID: 1697402]
  97. Oncotarget. 2016 Jan 26;7(4):4522-30 [PMID: 26683225]
  98. Trends Cancer. 2020 Feb;6(2):78-81 [PMID: 32061307]
  99. J Hepatobiliary Pancreat Sci. 2018 Feb;25(2):155-161 [PMID: 29130611]
  100. Nat Protoc. 2010 Dec;5(12):1993-2004 [PMID: 21127492]
  101. Biochimie. 2006 Jul;88(7):897-904 [PMID: 16540230]
  102. JAMA Oncol. 2019 Oct 1;5(10):1473-1478 [PMID: 31369045]
  103. Sci Rep. 2020 Jan 23;10(1):1039 [PMID: 31974468]
  104. J Am Chem Soc. 2019 Mar 6;141(9):3817-3821 [PMID: 30789261]
  105. Clin Chem. 1999 Sep;45(9):1628-50 [PMID: 10471678]
  106. Adv Healthc Mater. 2018 Dec;7(24):e1801231 [PMID: 30565898]
  107. Biomaterials. 2013 May;34(15):3816-27 [PMID: 23465488]
  108. ACS Nano. 2017 Apr 25;11(4):3943-3949 [PMID: 28287705]
  109. ACS Appl Mater Interfaces. 2016 Oct 12;8(40):27360-27367 [PMID: 27648728]
  110. Small. 2019 Oct;15(43):e1901014 [PMID: 31478613]
  111. Oligonucleotides. 2011 Mar-Apr;21(2):93-100 [PMID: 21413890]
  112. Annu Rev Pharmacol Toxicol. 2010;50:237-57 [PMID: 20055704]
  113. Cancers (Basel). 2018 Feb 09;10(2): [PMID: 29425173]
  114. J Biol Chem. 2011 Jun 17;286(24):21896-905 [PMID: 21531729]
  115. Expert Rev Mol Diagn. 2014 Jan;14(1):97-106 [PMID: 24308340]
  116. Angew Chem Int Ed Engl. 2017 Sep 18;56(39):11916-11920 [PMID: 28834063]
  117. Nat Rev Drug Discov. 2006 Feb;5(2):123-32 [PMID: 16518379]
  118. Exp Cell Res. 2016 Feb 15;341(2):147-56 [PMID: 26821206]
  119. Lab Chip. 2017 Oct 25;17(21):3558-3577 [PMID: 28832692]
  120. Nature. 2017 May 4;545(7652):60-65 [PMID: 28397821]
  121. Recent Results Cancer Res. 2012;195:69-76 [PMID: 22527495]
  122. Mol Cells. 2014 Oct 31;37(10):742-6 [PMID: 25266702]
  123. Oncotarget. 2016 Apr 26;7(17):23182-96 [PMID: 26992239]
  124. Talanta. 2019 Dec 1;205:120129 [PMID: 31450438]
  125. ACS Nano. 2014 Jan 28;8(1):941-9 [PMID: 24313365]
  126. Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):4861 [PMID: 23533270]
  127. Cancer Res. 2018 Feb 1;78(3):798-808 [PMID: 29217761]
  128. J Mol Recognit. 2017 Apr;30(4): [PMID: 27891685]
  129. J Extracell Vesicles. 2018 Feb 26;7(1):1438727 [PMID: 29511462]
  130. Analyst. 2021 Jan 4;146(1):253-261 [PMID: 33107503]
  131. Nat Nanotechnol. 2018 Jan;13(1):82-89 [PMID: 29230043]
  132. Anal Chem. 2019 Feb 5;91(3):2425-2430 [PMID: 30620179]
  133. Lab Chip. 2016 Dec 20;17(1):178-185 [PMID: 27924973]
  134. Sci Rep. 2016 Jun 08;6:27121 [PMID: 27272884]
  135. Oncol Rep. 2014 Nov;32(5):2054-60 [PMID: 25175855]
  136. Anal Chem. 2019 Aug 20;91(16):10879-10886 [PMID: 31347355]
  137. Nat Rev Clin Oncol. 2017 Sep;14(9):531-548 [PMID: 28252003]
  138. Mol Ther Nucleic Acids. 2013 Jun 11;2:e98 [PMID: 23756353]
  139. Oncology. 2018;94(5):311-323 [PMID: 29533963]
  140. Anal Chem. 2013 Sep 3;85(17):8277-83 [PMID: 23895515]
  141. J Clin Invest. 2008 Jan;118(1):376-86 [PMID: 18060045]
  142. Nat Commun. 2015 May 11;6:6999 [PMID: 25959588]
  143. Nanoscale. 2019 May 28;11(20):10106-10113 [PMID: 31089660]
  144. Nucleic Acids Res. 2013 Apr;41(7):4266-83 [PMID: 23470998]
  145. Anal Chim Acta. 2019 Jul 31;1063:127-135 [PMID: 30967176]
  146. Sci Rep. 2015 Nov 25;5:16788 [PMID: 26603187]
  147. Sci Transl Med. 2019 Jun 12;11(496): [PMID: 31189720]
  148. Cancer Res. 2002 Jul 15;62(14):4029-33 [PMID: 12124337]
  149. Anal Chem. 2017 Nov 21;89(22):12327-12333 [PMID: 29069893]
  150. Nat Commun. 2017 Nov 22;8(1):1683 [PMID: 29162835]
  151. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2008 Dec;24(12):1133-6 [PMID: 19068192]
  152. PLoS One. 2021 Feb 12;16(2):e0246527 [PMID: 33577574]
  153. Cancers (Basel). 2019 Mar 12;11(3): [PMID: 30871104]
  154. Anal Chem. 2018 Dec 18;90(24):14207-14215 [PMID: 30372048]
  155. Anal Chem. 2018 Nov 20;90(22):13451-13458 [PMID: 30234974]
  156. ACS Nano. 2018 Jan 23;12(1):494-503 [PMID: 29286635]
  157. Anal Bioanal Chem. 2006 Jan;384(1):191-8 [PMID: 16315013]
  158. Anal Bioanal Chem. 2008 Feb;390(4):1067-75 [PMID: 18049815]
  159. J Am Chem Soc. 2017 Apr 19;139(15):5289-5292 [PMID: 28332837]
  160. Methods Mol Biol. 2015;1218:187-99 [PMID: 25319652]
  161. Sci Rep. 2016 Sep 23;6:33935 [PMID: 27659060]
  162. Tumour Biol. 2006;27(6):289-301 [PMID: 17033199]
  163. Chem Biol. 2008 Jul 21;15(7):675-82 [PMID: 18635004]
  164. Cytometry A. 2004 Jun;59(2):220-31 [PMID: 15170601]

MeSH Term

Aptamers, Nucleotide
Biomarkers, Tumor
Early Detection of Cancer
Extracellular Vesicles
Humans
Ligands
Liquid Biopsy
Neoplasms
SELEX Aptamer Technique

Chemicals

Aptamers, Nucleotide
Biomarkers, Tumor
Ligands
Journal Article Review
Article has an altmetric score of 4

Word Cloud

Created with Highcharts 10.0.0earlycancerbiopsydetectionliquidcirculatingtreatmentdiseaseLiquidpromisingnon-invasivehighspecificityaffinityfavorsgreaterchancecurativelong-termsurvivalExcitingnewtechnologiesdevelopedcanhelpcatchtooldetectevenstagewellcontinuouslymonitorprogressionefficacyVariousmethodsimplementedisolatepurifybio-analytesspecimensAptamersshortoligonucleotidesconsistingeitherDNARNAcapablebindingtargetmoleculesDueuniquepropertiesconsideredrecognitionligandsvarietytargetsisolatedfacilemodificationregulationaptamersreviewdiscussrecentprogressaptamer-mediatedassociatedchallengesfuturepotentialclinicalapplicationsPotentialAptamer-MediatedBiopsyEarlyDetectionCancerDNA-nanostructuresaptamerbiomarkerstumorcellsextracellularvesiclesdiagnosis

Similar Articles

Cited By